Click Guardian v2 Tracking Pixel
Appointment

Dr Belma Buturovic

Endocrinologist Specialist

Endocrinologist & Diabetologist

Book An Appointment
Locations
Dubai
Languages
English Serbia Croatian Slovenian Macedonian Bosnian

Bio

Dr. Belma is a highly dedicated Endocrinologist and Diabetologist having more than 26 years of rich experience as a practicing physician.

 

Dr. Belma completed the Faculty of Medicine in Yugoslavia in 1989. She passed the internal medicine exam in 1996, after four years of the specialization program. She finished Postgraduate studies in 1997, obtaining a Master of Science degree. Dr. Belma also completed the doctoral degree in the field of Diabetology in 2005. In 2010, she passed the Endocrinology and Diabetology specialization exams. She was elected as Assistant Professor at the Medical University of Sarajevo in 2006 and 5 years later she was promoted to Associate Professor.

 

Dr. Belma, has been treating patients with diabetes and endocrine disorders since 1990 and worked as the Head of Endocrinology Department for 8 years. She has made major contributions while working in government and private practice, and she has been extremely successful in the treatment of patients suffering from diabetes, obesity and endocrine diseases.

 

She has also written a number of scientific papers and a book about prediabetes and type 2 diabetes. As the key opinion leader for international pharmaceutical companies in Bosnia and Herzegovina, she had been engaged as a speaker at regional and national symposiums. She was the President and official organizer of The First Diabetes Congress in Federation Bosnia and Herzegovina.

 

She was on the advisory team for South Eastern Europe for Liraglutide – Victoza and long acting insulin Tresiba. Dr. Belma was the primary investigator for clinical trials in Diabetes and Neuropathy (Investigator Protocol #: CBT. 115959 – 007, EudraCT Number: 2010- 022377-34 sponsor ERGOMED, Clinical Research Ltd. United Kingdom. June 2011).

 

Achievements & Awards

  • America Embassy Sarajevo, Certificate of Appreciation awarded to Dr Belma Ascic Buturovic for superior customer service, dedication, professionalism and exceptional medical care and support to U.S Embassy Sarajevo. December, 2013.

 

Treatments

Dr. Belma has extensive experience in treatment of:

  • Reproductive disorders
  • Menstrual irregularities
  • Adrenal glands disorders
  • Hyperandrogenism
  • Male and female infertility
  • Thyroid gland disorder
  • Thyroid nodule treatment
  • Parathyroid gland evaluation and treatment of thyroid and parathyroid tumors.
  • Extensive experience in treatment of neuroendocrine tumors, MEN 1,2, adrenal gland tumors.
Education

Degrees

  • Associate professor of Internal medicine, Endocrinology / Diabetology Medical Faculty, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Head  of Hospital  for Endocrinology, Diabetology and Metabolic Disorders, University Clinical Center, Sarajevo , 2015.
  • Head of Endocrinology Department , Hospital for Endocrinology, Diabetology and Metabolic Disorders, University Clinical Center, Sarajevo,  2005 – 2015.

Academic Degrees

  • 1989 – Bachelor’s Degree Certificate in Medicine, Medical Facility, University of Sarajevo, Yugoslavia
  • 1996 – Specialist in Internal Medicine , Federal Ministry of Health, Bosnia and Herzegovina
  • 1997 – Master of Medical Science, Medical Faculty, University of Sarajevo , Bosnia and Herzegovina
  • 2005 – Doctorate in Medicine Science, PhD MD , Medical Faculty University of Sarajevo, Bosnia and Herzegovina
  • 2010 – Specialization in Endocrinology and Diabetology, Federal Ministry of Health, Bosnia and Herzegovina.
Publications
  1. Aščić – Buturović B., Burnazović – Ristić L., Mujanović-Narančić A., Effects of Therapy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulate Postprandial Glycemia Med.Arh.2014;68 (5):313-316.
  2. Improved Glycaemic Control with Insulin Glargine as Part of a Basal Basal bolus Regimen in T2DM Patients Inadequately Controlled on Premixed Therapy Med Arh. 2013: (67):342.
  3. Analysis of coronary risk factors in obese patients with hypothyroidism. Medicinski Žurnal, 2013. 19.(4):331-339.
  4. The influence of BMI in patients with type 2 diabetes mellitus on cholesterol levels and C – reactive protein Folia Medica, 2012. : 47 (2): 142-152.
  5. Rosuvastatin Augmentation in Diabetes Mellitus Type 2 Promise Favourable Lipid Profile Changes – Pilot study Folia Medica, Journal of Medical Faculty, 2010. 45 (2): 76 – 81
  6. Effects of BMI on Cardiovascular Risk Factors in Diabetes Mellitus Type 2 patients Medicinski žurnal, 2010 : 16 (4): 216- 220.
  7. Hypothyreosis and Anemia –Current facts HealthMed, 2010 :(4): 880- 884.
  8. Effects of aggressive approach to the multiple risk factors for diabetic nephropathy on proteinuria reduction in diabetes type 2 patients Bosn J Basic Med Sci. 2009 ;9(1):44-8.
  9. Effects of basal insulin analog and metformin on glycaemia control and weight as risk factors for endothelial dysfunction. Bosn J Basic Med Sci. 2008 :8 (4):309-12.
  10. Effect of biphasic insulin aspart 30 combined with metformin on glycaemic control in obese people with type 2 diabetes Bosn J Basic Med Sci. 2007. ;7 (4):335-8.
  11. The effects of combined insulin and metformin therapy in obese patients with diabetes mellitus type 2 in the early stage of the disease. Bosn J Basic MeSci. 2006;6(2): 54-8.
  12. Effects of hyperglycemia and iron deficiency on kidney and heart function in type 2 diabetes disease Bosn J Basic Med Sci. 2006 ;6(1):78-81.
  13. Cystatin C as a marker for detection of early renal failure in diabetes type 2 patients. Bosn J Basic Med Sci. 2005 ;5(4):68-71.
  14. Contemporary methods of prevention and treatment diabetic kidney disease . Med Arh. 2005;59 (1):54-6.
  15. Amylin–a partner hormone to insulin Med Arh. 2003;57(3):177-8.
  16. Insulin glargine reduce blood glucose level with less hypoglycaemic events. IDF 2009, 20 the World Diabetes Congress Montreal 2009. Canadian Diabetes Association.
  17. Effects of Metformin and Alfa Lipoic Acid on Insulin Resistance in Obese Women with PCSO – Case report The First Serbian Congress of Endocrinology is accredited by the European Accreditation Council, 2008.
  18. The Effects of Three Daily Doses of BIAsp30 on Postprandial Glycaemia in Type 2 Diabetes Patients Endocrinologia & Metabologia. 52 Suplemento 6 Parte II, 2008.
  19. Effects of the war on the course and therapy of diabetes disease. Meeting for the Implementation of the St Vincent Declaration, 1999. ICEC Istanbul.
  20. Connection between visceral obesity, insulin resistance and C reactive protein HealthMed. 2013. 7.(6): 1906 -1911.
  21. The link between endothelial dysfunction markers (C-reactive protein, fibrinogen and the von Wilebrand factor) and changes in the carotid artery intima- media in diabetic patients. Folia Medica. 2013. 48. (1).26-31.
  22. Coronary angiography review of anatomic variations of the coronary arteries. Medicinski žurnal . 2013. 19 (1): 43 – 47.
  23. Angiographic evaluation of the dominance patterns of coronary circulation. HealthMed. 2012. 6.(6): 2229 – 2233.
  24. The role of subclinical hypothyroidism in polycystic ovary syndrome. Medicinski žurnal, 2009. 15 (7): 34- 35.
  25. Insulin Analogs Enable Good Glycaemia Control Delaying the Progression of Nephropathy in Type 2 Diabetes Acta Clinica Croatica. (2009.) UDC 61 CODEN ACLCED 48: 1-44. The 4th Croatian Diabetes Congress with international participation.
  26. Does insulin glargine treatment affect reduction of CRP in obese patients with type 2 diabetes? IDF 2009, 20 the World Diabetes Congress Montreal 2009. Canadian Diabetes Association www.worlddiabetescongress.org
  27. Glicoregulation and Body Weight Changes in Obese Patients with Type 2 Diabetes Treated with Detemir and Glargin 2008. Endocrinologia & Metabologia. 52 Suplemento.

 

Related services

Start chat
1
Chat with us
Hello
I’d like to book an appointment